Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder or Post-Traumatic Stress Disorder, amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.

NEW YORK , Nov. 7, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Guggenheim 4th Annual Immunology and Neurology Day, November 14 th and 15th. Raj Mehra, Ph.D.

Seelos Therapeutics to Participate in the Guggenheim 4th Annual Immunology and Neurology Day

Jupiter Wellness

Mind Medicine MindMed

NanoViricides

Oblong

Smart Sand

Capstone Green Energy

Risk is part of investing. Even the most mature, well-established firms and stocks run the risk of declining to zero.

7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov.

-Seelos' SLS-002 (intranasal racemic ketamine) is believed to be the only drug in the psychedelic class currently being developed specifically to treat the symptoms of suicidality associated with major depression. -Seelos Senior Management will sponsor the Press Breakfast on Friday November 4 th at 8:30am and take part in 2 panel discussions on Saturday November 5 th.

Seelos Therapeutics to Sponsor and Participate in Wonderland, the World's Leading Psychedelic Event

Seelos will also present at the International Congress for Ataxia Research in November    NEW YORK , Oct. 25, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced dosing of the first patient in a registrational phase II/III study of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of spinocerebellar ataxia focusing on participants with type3 (SCA3, also known as Machado-Joseph disease) and also announced that it will participate in the International Congress for Ataxia Research (ICAR) in Dallas, Texas November 1 st – 4th, 2022.   Dr. David Biondi, DO, FAAN, from Seelos will present: Autophagy as a potential treatment pathway in Spinocerebellar Ataxia: SLS-005 (Trehalose injection, 90.5 mg/mL for intravenous infusion) at ICAR on Thursday, November 3 rd at 4:45pm CT.

Seelos Therapeutics Doses First Patient in a Registrational Phase II/III study of SLS-005 in Spinocerebellar Ataxia

Seelos has an interesting drug platform. They are planning to release critical data this year.

Seelos: Data This Year Is Critical

- ACT for ALS Funding is for an Expanded Access Program to Study SLS-005 in Amyotrophic Lateral Sclerosis Patients Who Do Not Qualify for Clinical Trials NEW YORK , Sept. 30, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will collaborate with the Sean M.

Seelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program Funded by a Grant from the National Institute of Neurological Disorders and Stroke under the Accelerating Access to Critical Therapies for ALS Act (ACT f

Acadia Healthcare

FRANKLIN, Tenn.--(BUSINESS WIRE)---- $ACHC--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that select facilities from its network of acute care behavioral health hospitals will participate in a registration directed trial to study participants with suicidal ideation and behavior with major depression. This study is sponsored by Seelos Therapeutics (NASDAQ: SEEL) for its SLS-002 investigational drug. Acadia hospitals that meet the criteria for participation as clinical trial sites will be

Select Acadia Healthcare Hospitals to Participate in Clinical Trial for Acute Suicidal Ideation and Behavior in Major Depression Drug

Aprea Therapeutics

Ardelyx

Gritstone Oncology Inc

Red Hot Biotech Penny Stocks To Watch Right Now The post Why The Stock Market Is Down Today & 4 Penny Stocks To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why The Stock Market Is Down Today & 4 Penny Stocks To Watch

- Acadia Healthcare is the Largest Stand-Alone Behavioral Health Company in the United States Operating a Network of Nearly 240 Behavioral Health Facilities in 39 States and Puerto Rico NEW YORK , Sept. 13, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the participation of Acadia Healthcare Company, Inc. (Nasdaq: ACHC) in the registration directed Proof of Concept study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).

Seelos Therapeutics Announces the Participation of Acadia Healthcare in the Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Microvast Holdings

Spectrum Pharma

Whether you're a seasoned trader making money with penny stocks or just

Penny Stocks To Buy: The Good, Bad, & Ugly & 3 To Watch Now

NEW YORK , Sept. 9, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Guggenheim Nantucket Therapeutics Conference, September 27 th to 29th.

Seelos Therapeutics to Participate in the Guggenheim Nantucket Therapeutics Conference

- Seelos' SLS-002 is currently being developed specifically to treat the symptoms of suicidality associated with major depression NEW YORK , Aug. 30, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in two upcoming psychedelic conferences: Jefferies Innovation in Mental Health Summit, Psychedelics and New Emerging Treatments, September 22nd in New York City, NY Cantor Neurology and Psychiatry Conference, October 6th in San Francisco, CA "Still, there remains a dire need for a therapeutic labeled to treat the symptoms of suicidality" Raj Mehra, Ph.D., Chairman and CEO of Seelos, and senior management will participate in fireside chats, presentations and 1x1 meetings at these upcoming events to discuss the ongoing registrational, double-blind, placebo-controlled study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).

Seelos Therapeutics to Participate in Two Upcoming Psychedelic Conferences

Bright Minds Biosciences

SciSparc Ltd

Psychedelics stocks, like Seelos Therapeutics (NASDAQ: SEEL ), Scisparc (NASDAQ: SPRC ) and Bright Minds Biosciences (NASDAQ: DRUG ), are taking off today. This morning, it was announced that the Michael J.

Why Are Psychedelics Stocks Up Today?

Cybin

Cyclacel Pharmaceuticals

Hot biotech penny stocks to watch thanks to MNMD stock today. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 4 Biotech Stocks To Watch This Week

Atai Life Sciences BV

COMPASS Pathways

Defiance Next Gen Altered Experience ETF

PSYK ETF

Advisorshares Psychedelics ETF

On July 13, 2022, two amendments passed in the House of Representatives that would provide psychedelic drug treatment to veterans and active duty service members. A documentary based on Michael Pollan's 2018 book, "How to Change Your Mind," is one of Netflix's most-watched shows.

The Growth Potential Of Psychedelics Stocks And ETFs

SLS-005 Study on the HEALEY ALS Platform is Expected to Complete Enrollment this Quarter; Top-Line Data Readout Expected Mid-2023 NEW YORK , July 18, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced dosing of the first patient in an open-label basket study of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) in Australia.    Seelos plans to conduct this 24-week, open-label basket study (ACTRN: 12621001755820) in Australia to evaluate the effectiveness of SLS-005 on disease progression and severity, as well as its safety and tolerability, in participants with ALS, spinocerebellar ataxia and Huntington's disease.

Seelos Therapeutics Doses First Patient in an Open Label Basket Study of SLS-005 in Amyotrophic Lateral Sclerosis in Australia and Provides an Enrollment Update of its Study on the HEALEY ALS Platform

- A Single Dose of SLS-004 Produced 19% Downregulation of mRNA and ~40% Reduction of Alpha-Synuclein Compared to the Control Group - These Results Support Advancing SLS-004 into Additional Preclinical Studies in Dementia with Lewy Bodies NEW YORK , June 9, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced data demonstrating a statistically significant (p

Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Dementia with Lewy Bodies

NEW YORK , May 18, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received a Notice of Allowance for U.S. patent application number 16/833,515 from the United States Patent and Trademark Office (USPTO) covering SLS-007 titled: "Structure-Based Peptide Inhibitors of Alpha-Synuclein Aggregation". This Notice of Allowance covers the method of treating several neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease (PD), Lewy body dementia and multiple system atrophy, through contacting alpha-synuclein (α-synuclein) protofilaments with an effective amount of SLS-007.

Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007

NEW YORK , May 12, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 2022 Jefferies Global Healthcare Conference, June 8-10, 2022. Raj Mehra, Ph.D.

Seelos Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference

NEW YORK , April 22, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the B. Riley Securities' Virtual Neuro and Ophthalmology Conference, April 27-28, 2022.

Seelos Therapeutics to Participate in the B. Riley Securities' Virtual Neuro and Ophthalmology Conference

NEW YORK , April 11, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today an amendment of the agreement with Phoenixus AG, formerly known as Vyera Pharmaceuticals AG ("Vyera"), for the development of SLS-002 (intranasal racemic ketamine) to repurchase in cash and stock the remaining royalties payable on any future net sales of SLS-002, all future success and commercial based milestones and the change of control fee in the event SLS-002 is acquired.   On March 6, 2018, Seelos entered into an asset purchase agreement (the "Purchase Agreement") with Vyera, currently known as Phoenixus AG, to acquire the assets and liabilities of Vyera's intranasal racemic ketamine program, which Seelos now calls SLS-002.

Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase the Remaining Royalties Payable to Phoenixus AG for SLS-002 (Intranasal Racemic Ketamine Program), All Future Success and Commercial Based Milestones and the Change of Control Fee

NEW YORK, March 8, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received an acknowledgement letter of a Clinical Trial Notification (CTN) from the Australian Government Department of Health Therapeutic Goods Administration (TGA) for a pilot study of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of patients with Alzheimer's disease.   "Trehalose's activity in Alzheimer's disease is unique as it inhibits both the beta-amyloid pathology and tau aggregates in preclinical rodent models.

Seelos Therapeutics Receives an Acknowledgement Letter of a Clinical Trial Notification from the Australian Government Department of Health Therapeutic Goods Administration for a Pilot Study of SLS-005 in Alzheimer's Disease

NEW YORK, March 7, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced its year-end 2021 business and clinical update. "In the second half of 2021, we continued to accomplish several significant milestones and continued to execute in the face of one of the most difficult environments for publicly-traded biotech companies that I've seen in my career," said Raj Mehra Ph.D.

Seelos Therapeutics Announces Year-End 2021 Business and Clinical Update

NEW YORK, Feb. 28, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the dosing of the first participants in its registrational Phase II/III trial studying the investigational treatment SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) on the HEALEY ALS Platform Trial. "Initiating this trial is a major achievement for Seelos and we are honored to be part of the HEALEY ALS Platform Trial.

Seelos Therapeutics Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos received communication from the FDA that its part 2 study will be considered registrational. This derisks the company considerably, although the only efficacy data we have so far is from an open label trial.

Seelos: FDA Action Makes It Highly Attractive

News for Seelos Therapeutics Stock (SEEL)